Cancer treatment and survivorship statistics, 2012
By R. Siegel, C. DeSantis, Katherine S. Virgo, K. Stein, A. Mariotto, Tenbroeck G. Smith, D. Cooper, T. Gansler, C. Lerro, S. Fedewa and 9 more. Ca, 2012
3,165 citations recorded by the source corpus.
Although there has been considerable progress in reducing cancer incidence in the United States, the number of cancer survivors continues to increase due to the aging and growth of the population and improvements in survival rates. As a result, it is increasingly important to understand the unique medical and psychosocial needs of survivors and be aware of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. To highlight the challenges and opportunities to serve these survivors, the American Cancer Society and the National Cancer Institute estimated the prevalence of cancer survivors on January 1, 2012 and January 1, 2022, by cancer site. Data from Surveillance, Epidemiology, and End Results (SEER) registries were used to describe median age and stage at diagnosis and survival; data from the National Cancer Data Base and the SEER‐Medicare Database were used to describe patterns of cancer treatment. An estimated 13.7 million Americans with a history of cancer were alive on January 1, 2012, and by January 1, 2022, that number will increase to nearly 18 million. The 3 most prevalent cancers among males are prostate (43%), colorectal (9%), and melanoma of the skin (7%), and those among females are breast (41%), uterine corpus (8%), and colorectal (8%). This article summarizes common cancer treatments, survival rates, and posttreatment concerns and introduces the new National Cancer Survivorship Resource Center, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers. CA Cancer J Clin 2012. Published 2012 American Cancer Society.
Subfields: Oncology, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/fc8d52e855e85ec3142d9bd96d96dc294c946352
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Mechanisms and insights into drug resistance in cancer (2013, background): “…successes have been made in the treatment of cancer, including most strikingly chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL) which have met with great success as well as many cases of pediatric leukemias, Hodgkin’s lymphomas, and testicular cancers (Siegel et al., 2012).”
- What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. (2014, background): “© 2014 by American Society of Clinical Oncology INTRODUCTION Anticancer treatments have brought about definite advances in patient survival rates.(1) However, treatment is associated with significant toxicity that is potentially life-threatening,(1) and can often result in poor treatment adherence, ”